The New England journal of medicine, 2021-01, Vol.384 (2), p.129-139
- Bhatt, Deepak L
- Szarek, Michael
- Pitt, Bertram
- Cannon, Christopher P
- Leiter, Lawrence A
- McGuire, Darren K
- Lewis, Julia B
- Riddle, Matthew C
- Inzucchi, Silvio E
- Kosiborod, Mikhail N
- Cherney, David Z.I
- Dwyer, Jamie P
- Scirica, Benjamin M
- Bailey, Clifford J
- Díaz, Rafael
- Ray, Kausik K
- Udell, Jacob A
- Lopes, Renato D
- Lapuerta, Pablo
- Steg, P. Gabriel
2021
Details
- Autor(en) / Beteiligte
- Bhatt, Deepak L
- Szarek, Michael
- Pitt, Bertram
- Cannon, Christopher P
- Leiter, Lawrence A
- McGuire, Darren K
- Lewis, Julia B
- Riddle, Matthew C
- Inzucchi, Silvio E
- Kosiborod, Mikhail N
- Cherney, David Z.I
- Dwyer, Jamie P
- Scirica, Benjamin M
- Bailey, Clifford J
- Díaz, Rafael
- Ray, Kausik K
- Udell, Jacob A
- Lopes, Renato D
- Lapuerta, Pablo
- Steg, P. Gabriel
- Titel
- Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
- Ist Teil von
- The New England journal of medicine, 2021-01, Vol.384 (2), p.129-139
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2021
- Link zum Volltext
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- In a trial involving 10,584 patients with diabetes and chronic kidney disease, sotagliflozin resulted in fewer total deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure than placebo. Diarrhea, mycotic infections, and diabetic ketoacidosis occurred with sotagliflozin.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa2030186Titel-ID: cdi_proquest_journals_2477703057
- Format
- –
- Schlagworte
- Adverse events, Aged, Cardiovascular diseases, Cardiovascular Diseases - epidemiology, Cardiovascular Diseases - mortality, Cerebral infarction, Chronic kidney failure, Comorbidity, Confidence intervals, Congestive heart failure, Corporate sponsorship, Creatinine, Diabetes, Diabetes mellitus (non-insulin dependent), Diabetes Mellitus, Type 2 - complications, Diabetes Mellitus, Type 2 - drug therapy, Diabetic ketoacidosis, Diabetic Ketoacidosis - chemically induced, Diarrhea, Diarrhea - chemically induced, Double-Blind Method, Drug therapy, Female, Glomerular filtration rate, Glucose, Glycosides - adverse effects, Glycosides - therapeutic use, Heart attacks, Heart failure, Hemoglobin, Hospitalization, Hospitalization - statistics & numerical data, Humans, Hypoglycemic agents, Ketoacidosis, Kidney diseases, Male, Middle Aged, Mycoses - etiology, Myocardial infarction, Patient outcomes, Patients, Placebos, Renal Insufficiency, Chronic - complications, Renal Insufficiency, Chronic - drug therapy, Risk factors, Sodium-glucose cotransporter, Sodium-Glucose Transporter 1 - antagonists & inhibitors, Sodium-Glucose Transporter 2 Inhibitors - adverse effects, Sodium-Glucose Transporter 2 Inhibitors - therapeutic use, Statistical analysis, Testing